AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10513040 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine in treating coronary artery disease (CAD)
Number of subjects: 0
Study 10513040 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of conventional and emerging risk factors for CVD in high-risk individuals
Number of subjects: 0
Study 10513040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-center and multinational randomized and epidemiological studies
Number of subjects: 0
Study 8822437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm deposition at 6 o'clock position
Number of subjects: 6860
Study 8822437 — intervention group
Group type: COMPARATOR
Intervention: Sperm deposition at 12 o'clock position
Number of subjects: 6860
Study 8822437 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane breakage type A
Number of subjects: 6860
Study 8822437 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane breakage type B
Number of subjects: 6860
Study 8822437 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane breakage type C
Number of subjects: 6860
Study 8822437 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane breakage type D
Number of subjects: 6860
Study 8822437 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane breakage type E
Number of subjects: 6860
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 50 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 100 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 5 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 10 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 25 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 300 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 50 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and glycine formulation 100 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin doses above 100 mg
Number of subjects: 0
Study 2126726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release aspirin doses of 50 mg and below
Number of subjects: 0
Study 30865629 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS) given to mothers and children during the first 1,000 days
Number of subjects: 0
Study 30865629 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 27919901 — intervention group
Group type: EXPERIMENTAL
Intervention: CD101 IV 50 mg
Number of subjects: 8
Study 27919901 — intervention group
Group type: EXPERIMENTAL
Intervention: CD101 IV 100 mg (once weekly for 2 weeks)
Number of subjects: 8
Study 27919901 — intervention group
Group type: EXPERIMENTAL
Intervention: CD101 IV 200 mg (once weekly for 2 weeks)
Number of subjects: 8
Study 27919901 — intervention group
Group type: EXPERIMENTAL
Intervention: CD101 IV 400 mg (once weekly for 3 weeks)
Number of subjects: 8
Study 27919901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 25145377 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg single dose
Number of subjects: 40
Study 25145377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23743101 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable low-intensity therapeutic ultrasound (LITUS) device
Number of subjects: 30
Study 23743101 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 30
Study 21808760 — intervention group
Group type: EXPERIMENTAL
Intervention: TiOblast™ (Astra Tech) implants
Number of subjects: 18
Study 21808760 — intervention group
Group type: COMPARATOR
Intervention: Brånemark (Nobel Biocare) implants
Number of subjects: 18
Study 21808760 — intervention group
Group type: COMPARATOR
Intervention: Natural dentition
Number of subjects: 18
Study 21808760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 18
Study 20098348 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP + traction
Number of subjects: 163
Study 20098348 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP
Number of subjects: 163
Study 20098348 — intervention group
Group type: COMPARATOR
Intervention: Traction
Number of subjects: 163
Study 17685740 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 17685740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 17685740 — intervention group
Group type: COMPARATOR
Intervention: CBT-imipramine
Number of subjects: 0
Study 17685740 — intervention group
Group type: COMPARATOR
Intervention: CBT-paroxetine
Number of subjects: 0
Study 17685740 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study 16366040 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Vimpocetina)
Number of subjects: 24
Study 16366040 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 24
Study 11934971 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) 2% ointment applied for 1 minute
Number of subjects: 33
Study 11934971 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied for 1 minute
Number of subjects: 33
Study 11934971 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated finger)
Number of subjects: 33
Study 9469350 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V.‐oral regimen
Number of subjects: 12
Study 9469350 — intervention group
Group type: COMPARATOR
Intervention: I.V. mesna regimen
Number of subjects: 12
Study 7612061 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 150 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Number of subjects: 196
Study 7612061 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 300 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Number of subjects: 196
Study 2242456 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily (increased to a maximum of 200 micrograms daily)
Number of subjects: 33
Study 2242456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 38176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 569
Study 38176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 569
Study 38176 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 569
Study 38176 — intervention group
Group type: COMPARATOR
Intervention: None of the drugs
Number of subjects: 569
Study 30954442 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 71
Study 30954442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 28220604 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention promoting healthy diet, physical activity and gestational weight gain
Number of subjects: 100
Study 28220604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 26287417 — intervention group
Group type: EXPERIMENTAL
Intervention: PPB‐R‐203
Number of subjects: 84
Study 26287417 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 23872125 — intervention group
Group type: EXPERIMENTAL
Intervention: C500 (C0+500 g/t aflatoxin biodegradation preparations)
Number of subjects: 60
Study 23872125 — intervention group
Group type: EXPERIMENTAL
Intervention: C1000 (C0+1000 g/t aflatoxin biodegradation preparations)
Number of subjects: 60
Study 23872125 — intervention group
Group type: EXPERIMENTAL
Intervention: M500 (M0+500 g/t aflatoxin biodegradation preparations)
Number of subjects: 60
Study 23872125 — intervention group
Group type: EXPERIMENTAL
Intervention: M1000 (M0+1000 g/t aflatoxin biodegradation preparations)
Number of subjects: 60
Study 23872125 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (M0+2000 g/t aflatoxin biodegradation preparations)
Number of subjects: 60
Study 23872125 — intervention group
Group type: COMPARATOR
Intervention: C0 (basal diet)
Number of subjects: 60
Study 23872125 — intervention group
Group type: EXPERIMENTAL
Intervention: M0 (basal diet containing moldy peanut meal)
Number of subjects: 60
Study 21674848 — intervention group
Group type: COMPARATOR
Intervention: gabapentin
Number of subjects: 75
Study 21674848 — intervention group
Group type: COMPARATOR
Intervention: gabapentin-NSAID
Number of subjects: 75
Study 21674848 — intervention group
Group type: COMPARATOR
Intervention: gabapentin-NSAID-morphine
Number of subjects: 75
Study 21674848 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodal therapy (gabapentin-NSAID-morphine)
Number of subjects: 75
Study 21674848 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodal therapy
Number of subjects: 75
Study 19194671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting adjunct to botulinum toxin type-A and manual therapy
Number of subjects: 30
Study 19194671 — intervention group
Group type: COMPARATOR
Intervention: Standard care (botulinum toxin type-A and manual therapy)
Number of subjects: 30
Study 16963261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 147
Study 16963261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 15207941 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled lithium discontinuation (CLD) protocol
Number of subjects: 32
Study 11041313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.33, 0.65, 1.3 mg/70 kg)
Number of subjects: 0
Study 11041313 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 and 10 mg/70 kg)
Number of subjects: 0
Study 11041313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both opioids
Number of subjects: 0
Study 9347207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (NSAID) after the first dose of misoprostol
Number of subjects: 416
Study 9347207 — intervention group
Group type: COMPARATOR
Intervention: No nonsteroidal anti-inflammatory drug after the first dose of misoprostol
Number of subjects: 416
Study 9347207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Number of subjects: 416
Study 9347207 — intervention group
Group type: COMPARATOR
Intervention: No nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Number of subjects: 416
Study 8111210 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexotherapy (FR) plus conventional Western medicine (hypoglycemic agent)
Number of subjects: 32
Study 8111210 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine (hypoglycemic agent) only
Number of subjects: 32
Study 3089360 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt added to lentils (4.25 g)
Number of subjects: 6
Study 3089360 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt added to bread (4.25 g)
Number of subjects: 6
Study 29154602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco power wall behind the cashier
Number of subjects: 148
Study 29154602 — intervention group
Group type: COMPARATOR
Intervention: Tobacco power wall hidden behind an opaque wall
Number of subjects: 148
Study 26189587 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage nurse initiated radiography using the Ottawa Ankle Rules (OAR)
Number of subjects: 146
Study 26189587 — intervention group
Group type: COMPARATOR
Intervention: Standard triage
Number of subjects: 146
Study 25267802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 20
Study 25267802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 20
Study 25267802 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50 mg
Number of subjects: 20
Study 25267802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25267802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol in sildenafil responders
Number of subjects: 20
Study 25267802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol in sildenafil nonresponders
Number of subjects: 20
Study 22362559 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 1 mg/kg followed by TNK-tPA
Number of subjects: 45
Study 22362559 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental IV enoxaparin 0.3 mg/kg
Number of subjects: 45
Study 22362559 — intervention group
Group type: COMPARATOR
Intervention: No IV enoxaparin
Number of subjects: 45
Study 22362559 — intervention group
Group type: EXPERIMENTAL
Intervention: IV enoxaparin 0.3 mg/kg
Number of subjects: 45
Study 22362559 — intervention group
Group type: EXPERIMENTAL
Intervention: IV enoxaparin 0.5 mg/kg
Number of subjects: 45
Study 20035146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg once daily
Number of subjects: 30
Study 20035146 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily
Number of subjects: 30
Study 18694989 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention specialist intervention with 3-day training and ongoing support
Number of subjects: 30
Study 18694989 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention specialist intervention
Number of subjects: 30
Study 18694989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retention specialist)
Number of subjects: 30
Study 16350719 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone i.v. pulses followed by oral prednisone treatment (Group I)
Number of subjects: 60
Study 16350719 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thyroid drugs (Group II)
Number of subjects: 60
Study 16350719 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Group III)
Number of subjects: 60
Study 12045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient global assessment
Number of subjects: 294
Study 12045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability instruments and pain scale
Number of subjects: 294
Study 12045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 294
Study 10223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Total skin electron beam radiation (32-40 Gy, 4-6 MeV electrons)
Number of subjects: 45
Study 10223240 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense radiation (32-40 Gy, 4-6 MeV electrons)
Number of subjects: 45
Study 10223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Total skin electron beam radiation
Number of subjects: 45
Study 7878754 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-ME (microemulsion formulation)
Number of subjects: 0
Study 7878754 — intervention group
Group type: COMPARATOR
Intervention: CsA-GC (corn oil-based soft gel cap)
Number of subjects: 0
Study 7878754 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-ME
Number of subjects: 0
Study 2228847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g iv
Number of subjects: 120
Study 2228847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 666154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory ECG monitoring
Number of subjects: 70
Study 666154 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded treadmill exercise
Number of subjects: 70
Study 666154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of both tests
Number of subjects: 70
Study 30497490 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR) intervention
Number of subjects: 454
Study 30497490 — intervention group
Group type: COMPARATOR
Intervention: Control (no CCR)
Number of subjects: 454
Study 26861007 — intervention group
Group type: EXPERIMENTAL
Intervention: IAP18
Number of subjects: 50
Study 26861007 — intervention group
Group type: COMPARATOR
Intervention: IAP12
Number of subjects: 50
Study 26861007 — intervention group
Group type: EXPERIMENTAL
Intervention: IAP12 and IAP18
Number of subjects: 50
Study 24885412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group received electrical stimulation on the tongue that they could perceive
Number of subjects: 20
Study 24885412 — intervention group
Group type: COMPARATOR
Intervention: Control group used a device that did not provide a physiologically significant stimulus and was not perceivable
Number of subjects: 20
Study 22547251 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kcal/kg per week
Number of subjects: 404
Study 22547251 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal/kg per week
Number of subjects: 404
Study 22547251 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kcal/kg per week
Number of subjects: 404
Study 22547251 — intervention group
Group type: COMPARATOR
Intervention: Control (nonexercise)
Number of subjects: 404
Study 20333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser treatment
Number of subjects: 28
Study 18319355 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise for 3 months followed by 3 months of unsupervised exercise
Number of subjects: 60
Study 18319355 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise for 3 months
Number of subjects: 60
Study 18319355 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice alone (control)
Number of subjects: 60
Study 15813141 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated tents (0.4% permethrin)
Number of subjects: 545
Study 15813141 — intervention group
Group type: COMPARATOR
Intervention: Insect repellent
Number of subjects: 545
Study 15813141 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated tents
Number of subjects: 545
Study 12421432 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 63
Study 12421432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10379481 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (one hour at a maximum of 60% oxygen consumption)
Number of subjects: 6
Study 10379481 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise
Number of subjects: 6
Study 10379481 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy age-matched subjects)
Number of subjects: 6
Study 8727946 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin-sealed knitted Dacron prosthesis (GDP)
Number of subjects: 50
Study 8727946 — intervention group
Group type: COMPARATOR
Intervention: Unsealed knitted Dacron prostheses (UDP)
Number of subjects: 50
Study 1944909 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (2,300 mg/d)
Number of subjects: 56
Study 1944909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1944909 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 56
Study 6842003 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole plus nystatin
Number of subjects: 62
Study 6842003 — intervention group
Group type: COMPARATOR
Intervention: nalidixic acid plus nystatin
Number of subjects: 62
Study 31583708 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based exposure treatment
Number of subjects: 36
Study 31583708 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (Control)
Number of subjects: 36
Study 30506226 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) with precoated brackets (Group IV)
Number of subjects: 63
Study 30506226 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional two-step etch and primer method (CEM) with precoated brackets (Group II)
Number of subjects: 63
Study 30506226 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) with uncoated brackets (Group III)
Number of subjects: 63
Study 30506226 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-step etch and primer method (CEM) with uncoated brackets (Group I)
Number of subjects: 63
Study 28231036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% with dexamethasone 0.1%
Number of subjects: 68
Study 28231036 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% alone
Number of subjects: 68
Study 25828372 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS Expert stent
Number of subjects: 243
Study 25828372 — intervention group
Group type: COMPARATOR
Intervention: regular drug-eluting stent (rDES)
Number of subjects: 243
Study 25828372 — intervention group
Group type: EXPERIMENTAL
Intervention: Final kissing balloon (FKB) inflation in BiOSS Expert
Number of subjects: 243
Study 25828372 — intervention group
Group type: COMPARATOR
Intervention: Final kissing balloon (FKB) inflation in rDES
Number of subjects: 243
Study 25138273 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative perineural ropivacaine 0.2%
Number of subjects: 20
Study 25138273 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study 22677235 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 98
Study 22677235 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 98
Study 20461537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 306
Study 20461537 — intervention group
Group type: COMPARATOR
Intervention: Darn procedure
Number of subjects: 306
Study 18694444 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electroacupuncture (TEA)
Number of subjects: 27
Study 15699686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 74
Study 15699686 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 74
Study 11943440 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment A
Number of subjects: 0
Study 11943440 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment B
Number of subjects: 0
Study 10086650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g/day
Number of subjects: 40
Study 10086650 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 4 g/day
Number of subjects: 40